2.98
-0.33%
Close of 9 Nov 2026, in NOK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nykode Therapeutics A
Its shares trade on Oslo Børs under the ticker NYKD.OL. It has been listed since 27 January 2020. In the fiscal year to 31 December 2024, it reported revenue of $8.7m and a net loss of $38.8m. At that date it held total assets of $153.5m and shareholders' equity of $136.2m.
Vaccibody AS is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo. The company went IPO on 2020-01-27. The company is engaged in the development of vaccines that overcome the shortcomings of current vaccine technologies. The firm's vaccine platform increases the antibody and T-cell responses. The firm focuses on cancer vaccines, partnering the technology within infection and veterinary use. The firm develops of an immuntherapy against HPV-induced malignancies, such as precanceous lesions of cervical cancer. The major shareholders of the Company are BMI, Sarsia Seed and the investors.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 27 Jan 2020
- Employees
- 36
- Website
- vaccibody.com ↗
Leadership
Pay as last reported
- Mr. Martin NicklassonChairman of the Board, since 2021$2,000
- Mr. Michael EngsigChief Executive Officer$567,000
- Mr. Harald GurvinChief Financial Officer
- Ms. Elise RamseChief Human Resource Officer
- Ms. Mette HusbynChief Technical Officer
- Dr. Mikkel PedersenChief Scientific Officer
- Dr. Klaus EdvardsenChief Development Officer
- Mr. Peter FatumDirector, Head of QA
- Dr. Agnete FredriksenChief Innovation and Strategy Officer, since 2021
- Ms. Katrine HusumSenior Director, Head of Project and Alliance Management
- Ms. Siri TorhaugChief Medical Officer
- Mr. Christian AbyholmDirector$33,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Advanced technology and expertise in the development of therapeutic vaccines.
- Strong intellectual property portfolio providing a competitive advantage in the market.
- Strategic collaborations with reputable pharmaceutical companies, enhancing research and development capabilities.
- Well-established network of research partners and key opinion leaders in the field.
Weaknesses
- Relatively small size and limited resources compared to larger pharmaceutical companies.
- Dependency on successful clinical trial outcomes to generate revenues.
- Limited product portfolio with focus on specific therapeutic areas.
Opportunities
- Increasing demand for personalized medicine and targeted therapies.
- Growing global healthcare expenditure, providing opportunities for market expansion.
- Emerging markets with unmet medical needs, offering potential for partnerships and market penetration.
Threats
- Intense competition from established pharmaceutical companies and new entrants in the field of therapeutic vaccines.
- Stringent regulatory requirements and approval processes for drug development.
- Potential risks associated with adverse events during clinical trials, leading to setbacks and negative publicity.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.